Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Apr 20 2010

Atherotech Inc. announced it will exhibit its VAP® Cholesterol Test in booth #1305 at Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP). The meeting takes place April 22-24, 2010, at the Metro Toronto Convention Centre in Toronto, Canada.

The VAP Test reports 22 separate components of cholesterol in a single test, including Lp(a), apoB, apoAI, and the apoB/apoAI ratio, at no additional cost, which saves health care dollars and maximizes risk identification. The VAP Test also identifies markers of metabolic syndrome, often associated with early diabetes.

"The VAP Cholesterol Test is gaining momentum as the preferred lipid test," said Atherotech Chief Medical Officer Michael E. Cobble, M.D. "Internal Medicine 2010 attendees will learn how we're complementing our VAP Test with the addition of cardiometabolic and genetic testing, giving physicians and cardiology practices a single source for multiple test panels."

Atherotech provides physicians with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests. Cardiometabolic testing available through Atherotech includes C-Reactive Protein (hsCRP), LpPLA2, ApoE genotype, NT-proBNP, Cystatin-C, T3 and T4 when TSH is abnormal, plus gamma-glutamyl transferase (GGT), a recognized cardiovascular risk biomarker.

Atherotech representatives will be available to discuss new research, the VAP Test and cardiometabolic test options throughout the conference. Blood draws will be provided to qualified attendees during regular exhibit hours. Unlike the standard lipid profile, the VAP Test directly measures LDL, therefore fasting is not required.